IP Library Granted Patent US 8,410,103
Granted Patent B2
US 8,410,103 · App. 13/352,686 · Granted Apr 2, 2013

(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent

Inventors: Brian Alvin Johns (Research Triangle Park, NC); Takashi Kawasuji (Osaka, JP); Teruhiko Taishi (Osaka, JP); Yoshiyuki Taoda (Osaka, JP)
Assignees: Shionogi & Co., Ltd.; VIIV Healthcare Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,410,103
App. No.
13/352,686
Granted
Apr 2, 2013
Kind
B2
Abstract

The present invention is directed to a substituted 2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2 -a]pyrido[1,2-d]pyrazine-5,7-dione useful as an anti-HIV agent, which has the formula: as well as pharmaceutically acceptable salts thereof, compostions thereof, and methods of use thereof.

Claims (7)

1. A compound which is (3S,11aR)—N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising (3S,11aR)—N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

3. A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of (3S,11aR)—N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide or a pharmaceutically acceptable salt thereof.

4. A compound which is (3S,11aR)—N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide sodium salt.

5. A pharmaceutical composition comprising (3S,11aR)—N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide sodium salt together with a pharmaceutically acceptable carrier or diluent.

6. A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide sodium salt.

7. A compound of the formula:

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2024
From: JOHNS, BRIAN ALVIN
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 068606/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2024
From: KAWASUJI, TAKASHI; TAISHI, TERUHIKO; TAODA, YOSHIYUKI
To: SHIONOGI & CO. LTD.
Reel/Frame 068606/0866 →
CHANGE OF NAME Recorded Sep 17, 2024
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 068970/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2012
From: GLAXOSMITHKLINE LLC
To: VIIV HEALTHCARE COMPANY
Reel/Frame 029136/0545 →
Priority Claims (2)
JP 2005-131161 · Apr 28, 2005 · national
JP 2005-312076 · Oct 27, 2005 · national
Continuity (2)
Division 11919386
Related Publication 20120115875A1 · May 10, 2012